one-month history of epigastric pain and dyspepsia. He was diagnosed with hypertension eight years previously, and consequently was being treated with oral antihypertensive medication.
Five years earlier, he had been diagnosed with seropositive rheumatoid arthritis and Raynaud's syndrome, and had used non-steroidal anti-inflammatory drugs (NSAIDs) as needed. At admission, his blood pressure was 120/80 mmHg, his pulse rate was 89 BPM, and his body temperature was 36.2℃. He had ingested alcohol for 20 years and did not smoke. On physical examination, he reported radiating pain in his back.
A complete blood count showed a hemoglobin level of 14.6 g/dL, hematocrit of 43.2%, white blood cell count of 5,290/mL, and platelet count of 230,000 /µL. To rule out pain originating from his pancreas, amylase, lipase, and CA 19-9 testing were performed and found to be within normal limits. His sodium level was slightly decreased at 136 mM/L (normal range, 138-148 mM/L), but potassium, chloride, and calcium levels were all normal.
Chest radiography was normal with no hilar lymphadenopathy. Abdominopelvic CT (APCT) scans demonstrated large bilateral adrenal masses, which were probably the cause of his radiating back pain. The left adrenal gland measured 5.0 x 6.2 x 6.0 cm and the right adrenal gland measured 3.7 x 5.7 x 5.0 cm. The left adrenal gland mass was heterogeneously enhanced and invaded to the left crus. Another small, enhanced lymph node (LN) measuring 2.0 cm was also noted around the superior pole of the left kidney. The right adrenal gland mass was also heterogeneously enhanced, directly invaded segment 1 (S1) of the liver, and partially invaded the right crus. A 2.8-cm enlarged LN in the retrocaval area and several enlarged LNs with some necrosis in the aortocaval and left paraaortic area were also noted ( Fig. 1 ).
Laboratory tests to evaluate the bilateral adrenal masses were also performed. Serum β2-microglobulin concentration was slightly increased The findings of the EGD and colonoscopy were also normal.
Fig. 1. (a) re-contrast APCT scan shows large, homogeneous soft tissue masses in bilateral adrenal glands (asterisks)(b,c,d) ontrast-enhanced APCT scan shows adjacent lymph node enlargement (straight arrow), retroperitoneal enlarged lymph nodes involving internal necrosis (dotted arrow), adjacent liver (double-lined arrow) and crural invasion (curved arrow).
Relying only on laboratory and radiologic findings, we could not differentiate between ACC and PAL. Adjacent organ invasion and heterogeneous enhancement after IV contrast medium was ad- (Fig. 2c ). This patient continues to be followed up without definitive evidence of recurrence. type is diffuse large B-cell lymphoma. 2 PAL is most common in elderly men; the mean age at diagnosis is 68 years and the male-to-female ratio is 2.2:1.
DISCUSSION
Clinical symptoms of PAL include fever, weight loss, localized pain, and symptoms of adrenal insufficiency. 3 Immune dysfunction may be a predisposing factor in some patients. 4 There has been a lack of uniform consensus on the definition of PAL in the past. 12 Recently, however, there have been efforts to better define this disease entity. 13 In addition, the previously reported cases only showed adrenal involvement without other areas of abnormal uptake. Unfortunately, both ACC and PAL are highly FDG-avid so we cannot differentiate these two malignant tumors by F-18 FDG PET/CT; however, F-18 FDG PET/CT can reveal staging, local recurrence, and the result of treatment follow-up. 15 Our case showed successful treatment response, with decreased FDG avidity in adrenal lesions and metastatic lymph nodes, and the involved adrenal glands returning to their original size and configuration.
In conclusion, PAL is a very rare entity, so only limited cases using F-18 FDG PET/CT have been reported. Our patient showed highly FDG-avid PAL mimicking adrenocortical carcinoma before biopsy. He had nearly complete remission after three cycles of R-CHOP, and the size was even more decreased after six cycles of R-CHOP. These results suggest the possibility for evaluation of early responsiveness of chemotherapy using F-18 FDG PET/CT.
